image description

Tag: Gazyva

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

FDA Expedites Existing Drug Gazyva for Lupus Nephritis

September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus.  The FDA’s designation aims to  speed up  the development and review of drugs intended to treat a serious condition […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates